Catheter Precision, Inc. (VTAK) AI Stock Analysis

Headquartered in Fort Mill, South Carolina, Catheter Precision, Inc. designs, manufactures, and distributes medical technologies for cardiac electrophysiology applications in the United States. Its core offering is the View into Ventricular Onset System, a non-invasive 3D cardiac mapping imaging platform that localizes the origins of idiopathic ventricular arrhythmias in structurally normal hearts. The company also offers the LockeT suture retention device for temporary suture security and removal, as well as the Amigo Remote Catheter System, a robotic arm designed for remote catheter control during cardiac procedures. Products are distributed through direct sales personnel, independent sales agents, and distribution partners.

Catheter Precision has seen fluctuating annual sales, with revenue increasing from $420,000 in FY2024 to $819,000 in FY2025, representing revenue growth of 95.0%. Despite this, 5-year revenue CAGR from FY2020 to FY2025 stands at -28.6%. Gross margin remained high at 92.3% in FY2025, compared to 90.0% in FY2024 and 93.2% in FY2023. However, operating losses remain substantial, with FY2025 operating margin at -1487.3% and net income at -$17.2M. For the latest quarter ended June 30, 2026, quarterly revenue grew 380.7% year-over-year, lifting trailing twelve-month revenue to $1.9M, though operating margin stood at -388.1%.

As of June 30, 2026, Catheter Precision held $1.8M in cash and short-term investments against total debt of $3.3M, leaving net debt of $1.5M. The company reported total assets of $36.9M and shareholders' equity of $17.6M, resulting in a debt-to-equity ratio of 0.19 and a current ratio of 0.19. In FY2025, operating cash flow was -$8.3M and free cash flow was -$8.3M, while capital expenditures were $17,000. Over a 5-year period, the company's share count increased 1953.0%.

At a closing price of $0.84 on October 16, 2026, Catheter Precision trades at a market cap of $286,477 and an enterprise value of $12.4M. Its price-to-sales multiple is 0.1x, compared to the median of 4.1x for its US-listed Healthcare peers. The company's EV-to-EBITDA stands at 0.3x, compared to the peer median of 12.0x, while its EV-to-revenue is 6.5x. Over the past year, the stock fell 68.1%, while the S&P 500 benchmark gained 16.8%.

Wall Street coverage includes 1 analyst rating, categorized as Strong Buy. The mean price target is $2.00, representing an upside of 138.1% from the last close of $0.84. Over the last 4 quarters, the company delivered 0 earnings beats. For the next fiscal year, the consensus revenue estimate is $10.2M, projecting revenue growth of 167.8%, while the EPS estimate is -$0.32, an estimated improvement of 49.2%. The next earnings date is November 12, 2026.

This page is an AI-written research summary of Catheter Precision, Inc. (VTAK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VTAK income statement, VTAK balance sheet, VTAK key metrics, VTAK analyst forecast, VTAK chart. See the VTAK stock overview for the latest quote and news.